Therefore, PHI was approved by the FDA (Food and Drug Administration) and has been established as a PCa biomarker for men over 50 years of age with negative digital rectal examination and PSA in the grey zone (between 4 and 10 ng/mL) to improve diagnostic accuracy and avoid unnecessary biopsies (Table 1). This evidence concerns the gene KLK3 and posterior cortical atrophy.